Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1890-1910

Bentham Science Publishers

Access to resources Recommend Favorite

Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-07 ,pp. : 1529-1543

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy

By Frankenne F.   Noel A.   Bajou K.   Sounni N.   Goffin F.   Masson V.   Munaut C.   Remacle A.   Foidart J.  

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 3, 1999-09 ,pp. : 469-481

Informa Healthcare

Access to resources Recommend Favorite

uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1744-1760

Bentham Science Publishers

Access to resources Recommend Favorite

Regulation of the Urokinase Receptor (uPAR) by LDL Receptor-related Protein-1 (LRP1)

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1962-1969

Bentham Science Publishers

Access to resources Recommend Favorite